The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Rawcliffe Adrian since 2018.
This trader's CIK number is 1555851.
At the time of last reporting, Rawcliffe Adrian was the Chief Executive Officer of Adaptimmune Therapeutics Plc. (stock ticker symbol ADAP).
Also see all insider trading activities at Adaptimmune Therapeutics Plc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | ADAP | 0 | $0 | 90,170 | $52,427 | 0 | $0 |
| 2024 | ADAP | 0 | $0 | 68,586 | $52,327 | 0 | $0 |
| 2023 | ADAP | 0 | $0 | 51,671 | $86,091 | 0 | $0 |
| 2022 | ADAP | 0 | $0 | 39,134 | $128,949 | 0 | $0 |
| 2021 | ADAP | 0 | $0 | 23,129 | $125,791 | 0 | $0 |
| 2020 | ADAP | 0 | $0 | 14,700 | $73,122 | 0 | $0 |
| 2019 | ADAP | 0 | $0 | 3,084 | $16,557 | 0 | $0 |
| 2018 | ADAP | 0 | $0 | 600,000 | $1,026,000 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-17 | ADAP | Sale | 30,601 | .58 | 17,779 |
| 2025-01-13 | ADAP | Sale | 30,473 | .59 | 17,918 |
| 2025-01-15 | ADAP | Sale | 29,096 | .57 | 16,730 |
| 2024-01-16 | ADAP | Sale | 9,304 | .79 | 7,350 |
| 2024-01-17 | ADAP | Sale | 30,080 | .67 | 20,243 |
| 2024-01-11 | ADAP | Sale | 11,945 | .84 | 9,997 |
| 2024-01-12 | ADAP | Sale | 17,257 | .85 | 14,737 |
| 2023-09-01 | ADAP | Sale | 2,403 | .78 | 1,874 |
| 2023-06-27 | ADAP | Sale | 2,333 | .92 | 2,146 |
| 2023-01-17 | ADAP | Sale | 10,057 | 1.86 | 18,685 |
| 2023-01-11 | ADAP | Sale | 13,042 | 1.75 | 22,784 |
| 2023-01-12 | ADAP | Sale | 18,763 | 1.71 | 32,009 |
| 2023-01-04 | ADAP | Sale | 5,073 | 1.69 | 8,593 |
| 2022-09-01 | ADAP | Sale | 2,536 | 1.97 | 4,993 |
| 2022-06-27 | ADAP | Sale | 2,562 | 1.63 | 4,176 |
| 2022-01-18 | ADAP | Sale | 11,096 | 3.19 | 35,418 |
| 2022-01-11 | ADAP | Sale | 14,362 | 3.56 | 51,085 |
| 2022-01-12 | ADAP | Sale | 3,046 | 3.54 | 10,795 |
| 2022-01-04 | ADAP | Sale | 5,532 | 4.06 | 22,482 |
| 2021-09-01 | ADAP] | Sale | 2,782 | 5.20 | 14,452 |
| 2021-06-28 | ADAP | Sale | 2,794 | 4.37 | 12,209 |
| 2021-01-19 | ADAP | Sale | 9,879 | 5.67 | 56,013 |
| 2021-01-12 | ADAP | Sale | 2,707 | 6.15 | 16,653 |
| 2021-01-04 | ADAP | Sale | 4,967 | 5.33 | 26,464 |
| 2020-09-01 | ADAP | Sale | 2,776 | 8.52 | 23,637 |
| 2020-08-03 | ADAP | Sale | 2,788 | 9.25 | 25,789 |
| 2020-01-14 | ADAP | Sale | 3,236 | 5.13 | 16,616 |
| 2020-01-06 | ADAP | Sale | 5,900 | 1.20 | 7,080 |
| 2019-01-14 | ADAP | Sale | 3,084 | 5.37 | 16,557 |
| 2018-03-20 | ADAP | Sale | 600,000 | 1.71 | 1,026,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Rawcliffe Adrian (Chief Executive Officer of Adaptimmune Therapeutics Plc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.